IZQVF - Indivior PLC

Other OTC - Other OTC Delayed Price. Currency in USD

Indivior PLC

10710 Midlothian Turnpike
North Chesterfield, VA 23235
United States
804 379 1090
http://www.indivior.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees915

Key Executives

NameTitlePayExercisedYear Born
Mr. Shaun ThaxterCEO & Exec. Director1.01MN/AN/A
Mr. Mark CrossleyCFO & Exec. Director550.8kN/AN/A
Dr. Christian HeidbrederChief Scientific OfficerN/AN/AN/A
Mr. Ingo ElferingChief Information & Innovation OfficerN/AN/AN/A
Mr. Jason ThompsonVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Corporate Governance

Indivior PLC’s ISS Governance QualityScore as of April 1, 2019 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.